IDEAYA Biosciences (IDYA) Corporate presentation summary

Vision and strategy

• Aims to build a leading precision medicine oncology company with a focus on first- and best-in-class programs using predictive biomarkers and AI-driven drug discovery.

• Research targets neoadjuvant/adjuvant indications, 1L metastatic disease, rational combinations, and tumor heterogeneity.

Drug discovery platform

• Six internally discovered clinical-stage molecules address challenging targets like helicases, polymerases, and glycohydrolases.

• Core capabilities include CRISPR-based discovery, chemigenomics, AI-driven drug design, and novel selectivity profiles.

Darovasertib for uveal melanoma (UM)

• Targets PKC pathway, driven by GNAQ/11 mutations in >95% of UM patients, with potential to be first targeted therapy for all UM stages.

• Combination with crizotinib aims to improve survival in metastatic UM, regardless of HLA status.

• Phase 2/3 trials show median PFS of 7.0 months and OS of 21.1 months, outperforming historical data.

• Neoadjuvant trials demonstrate robust tumor shrinkage, eye preservation, and visual improvement.